Thioredoxin-interacting Protein Targets PRDX3 to Induce Mitochondria-associated Ferroptosi

Thioredoxin-interacting Protein Targets PRDX3 to Induce Mitochondria-associated Ferroptosi
PXD074828 · iProX

TL;DR — A 512.9 KB mass-spectrometry proteomics deposit (PXD074828, 1 file(s), liver) in the MASLD / NAFLD / NASH data lake. under-mined portal (iProX); large (15 GB); modality=proteomics.


0. Summary

Biological premise.

The following premise is sourced from the repository record (not fabricated).

Hepatocyte ferroptosis has emerged as a pivotal driver of metabolic dysfunction-associated steatotic liver disease (MASLD), yet the mechanisms coupling metabolic stress to the ferroptotic machinery remain elusive. Here, we identify thioredoxin-interacting protein (TXNIP) as a requisite mediator of mitochondria-associated ferroptosis during MASLD progression. Interrogation of clinical datasets and experimental models revealed that hepatic TXNIP is robustly upregulated in MASH patients, positively correlated with disease severity and pro-ferroptotic gene signatures. Txnip-deficient mice conferred significant protection against high-fat diet-induced steatohepatitis and hepatic ferroptosis. Mechanistically, metabolic stress triggers the mitochondrial translocation of TXNIP, where it directly interacts with the mitochondrial-specific peroxidase Peroxiredoxin 3 (PRDX3). This physical association suppresses PRDX3 antioxidant activity, leading to mitochondrial reactive oxygen species (ROS) accumulation, iron overload, and lipid peroxidation. Functional rescue experiments confirmed that PRDX3 overexpression effectively abrogates TXNIP-induced ferroptosis, whereas PRDX3 silencing exacerbates the ferroptotic phenotype in TXNIP-overexpressing cells. Collectively, these findings establish the TXNIP-PRDX3 axis as a critical regulatory hub for mitochondrial redox homeostasis and identify this interaction as a potential therapeutic vulnerability to arrest MASLD progression.

Every file in this dataset is a mass-spectrometry proteomics readout relevant to MASLD / non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), landed from iProX.

Assay and processing.

Modality: mass-spectrometry proteomics (repository subtype: proteomics). Tier-1 (must-have) for this modality = protein/peptide × sample quant matrix + sample→group design; Tier-2 (recommended) = peptide table, search params + FASTA + FDR, author DE tables, PTM sites; Tier-3 (optional / raw) = raw instrument spectra (.raw/.d/.mzML), exact FASTA. The Completeness line in each dataset block below states, measured from the landed files, which tiers are present.

Sources.

  • PXD074828 — iProX deposit (under-mined portal (iProX); large (15 GB); modality=proteomics).
  • PMIDs: none recorded in the index for this deposit.
DiseaseMASLD / NAFLD / NASH
Assay / modalitymass-spectrometry proteomics — proteomics
Organismsunspecified
RepositoryiProX — iProX (ProteomeXchange)
AccessionPXD074828
AccessPublic (open); files mirrored in this dataset's input/ folder.
Number of studies1
Number of files1
Total size512,898 bytes (≈ 512.9 KB)

1. Datasets — sample sources, protocols, experiment design and metadata

Landed sources at a glance.

SourceAccessFiles
iProXpublic / OPEN-processed1

The deposit at a glance.

AccessionDescriptionOrganismSamplesScale
PXD074828under-mined portal (iProX); large (15 GB); modality=proteomicsunspecifiedn/a1 files · 512.9 KB

PXD074828 — Thioredoxin-interacting Protein Targets PRDX3 to Induce Mitochondria-associated Ferroptosi

iProX record · 1 files · 512.9 KB

  • Sample source. unspecified material; MASLD/NAFLD/NASH context (under-mined portal (iProX); large (15 GB); modality=proteomics).

  • Samples and retention. Sample count not declared in the repository index; see the per-sample metadata file(s) listed below.

  • Experiment design. Repository subtype: proteomics; disease context MASLD/NAFLD/NASH.

  • Metadata available. See the annotated file table below; per-sample metadata ships in the ISA-Tab / SDRF / metadata file(s) where present.

  • Files (annotated).

    FileWhat it is
    search.xlsxSpreadsheet — processed data / supplementary table
  • How this experiment became a dataset. PXD074828 resolved via the iProX record API → 1 open file(s) fetched into this dataset's input/ folder → sizes verified on disk (512,898 bytes (≈ 512.9 KB)).

  • Completeness (mass-spectrometry proteomics). No canonical Tier-1 slot auto-detected among the landed files. Not detected among landed files: quant matrix (Tier-1); sample→group design (Tier-1); peptide table (Tier-2). (Tiers per the matching modality skill; assessment measured from landed filenames/headers.)


2. Analyses this atlas supports

  • Differential protein abundance. Start from search.xlsx (quant matrix); map samples→groups from the design/annotation file to build volcano/DE tables.
  • Cross-cohort MASLD integration. Combine this deposit (PXD074828) with other liver/MASLD datasets in the lake sharing the same modality for meta-analysis.

Reproduce. All files are in this dataset's input/ folder; the source of record is PXD074828 (https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD074828). Re-fetch with the MASLD crawler (masld_download_pass.py --only PXD074828); sizes are verified on disk and recorded in this dataset's metadata.json.


Citation

Thioredoxin-interacting Protein Targets PRDX3 to Induce Mitochondria-associated Ferroptosi. iProX accession PXD074828. https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD074828

About this dataset

This 10x Genomics dataset provides single-cell gene expression from liver samples, with disease state recorded as MASLD/NAFLD/NASH.

Analyze it in Drylab

Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:

  1. Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
  2. Normalize, select variable genes, then cluster the cells and draw a UMAP.
  3. Annotate clusters with marker genes and compare the cell-type mix between conditions.
  4. Run differential expression between cell types or samples to characterize masld/nafld/nash biology.